Where does Neuspera Medical Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Neuspera Medical Inc. ranks #17,030 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Neuspera Medical Inc. hold?

Neuspera Medical Inc. holds 17 US utility patents granted between 2017 and 2025, spanning 7 technology areas.

What is Neuspera Medical Inc.'s Innovation Score?

Neuspera Medical Inc. has an Innovation Score of 35.2 out of 100 (top 50% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Neuspera Medical Inc. focus on?

Neuspera Medical Inc.'s top technology area is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy) with 17 patents, ranking #211 of 1,943 assignees active in that subclass. Grants appear in 7 CPC subclasses total.

Is Neuspera Medical Inc.'s patent grant rate increasing or decreasing?

Neuspera Medical Inc.'s recent grant velocity is +267% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Neuspera Medical Inc.'s patents?

Neuspera Medical Inc.'s patents average 18.5 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Neuspera Medical Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Neuspera Medical Inc.

USPTO PatentsView assignee record - 17 granted patents across 7 technology areas, recorded in grant years 2017–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Neuspera ranks #17,030 of 49,997 tracked US assignees by granted-patent volume, with 17 patents across 7 technology areas.

#17,030
of 49,997 US assignees by volume: Top 50%
by Innovation Score (35.2/100): 18.5
avg claims per patent: +267%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R17030 · US Corporation #17,030 · 17 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 17 grants
MID-PACK #17,030/49,997
PHOTO-FINISH Neograf Solutions
CPC-NARROW A61N · 7 areas
INNOV-THIN 35.2/100
CLAIMS-RICH 18.5 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +267% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Neograf Solutions, LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Neuspera’s 35.2 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 10.0 pts (28%) Velocity 4.8 pts (14%) Breadth 9.4 pts (27%) Claim depth 11.1 pts (31%)

Qualcomm Incorporated · highest

85
Neuspera Medical · this assignee

35
3D Lighting… · lowest

7

What this shows Neuspera's Innovation Score is 35.2/100 (top 50% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Neuspera?

Each dot is one of Neuspera’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Neuspera’s own 18.5 claims/patent is ABOVE the 17.2 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Neuspera vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Neuspera's grants concentrate

Neuspera Medical Inc. is a focused PatentsView assignee: 7 CPC subclasses with 100% of grants classified under A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy). Peak complete grant year is 2021 (4 grants) versus a trough of 1 in 2019. By volume, Neuspera sits between Neograf Solutions, LLC and Next Carbon Solutions, LLC.

Neuspera's three-year grant acceleration

Neuspera Medical Inc. shows 5 grants in 2022–2024 against only 7 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Neograf Solutions

17
Neuboron Therapy…

17
Neuracle Science

17
Neuro Kinetics

17
NEW Power Plasma

17
NEX Services Nort…

17
Nexon Korea

17
Next Carbon Solut…

17
Neuspera Medical ◀

17

What this shows Neuspera holds 17 patents at rank #17,017, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Neuspera

By rank, the assignees closest to #17,017 in granted patent volume.

Leaders in A61N (Electrotherapy)

Other assignees with the most granted patents in Neuspera's primary technology class.

Neuspera's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

35 Top 50% higher than 50% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2017–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table

Neuspera Medical Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2017	2	11.8%
2019	1	5.9%
2020	2	11.8%
2021	4	23.5%
2022	1	5.9%
2023	1	5.9%
2024	3	17.6%
2025partial year	3	17.6%

Which technologies does Neuspera Medical Inc. patent most?

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 17

H02J - Circuit Arrangements OR Systems FOR Supplying OR Distributing Electric POWER; Systems FOR Storing Electric Energy 16

A61B - DIAGNOSIS; SURGERY; Identification 14

H04B - Transmission 4

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 4

H01G - CAPACITORS; Capacitors, Rectifiers, Detectors, Switching Devices, Light-sensitive OR Temperature-sensitive Devices OF THE Electrolytic Type 3

H01Q - Antennas, i.e. Radio Aerials 3

Top 7 of 7 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Neuspera Medical Inc.'s patent record in context - here's where to go next.

Neuspera Medical Inc.'s lead technology class is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy), 100% of its portfolio - see every assignee active in that class. Explore A61N
Ranked #17,030 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Neuspera Medical Inc. against Neograf Solutions, LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 35.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.